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Background: Sudden cardiac arrest (SCA) and death are feared events early post myocardial infarction (MI). Current guidelines proscribe 
implantable cardioverter-defibrillator (ICD) therapy for 40 days or 90 days post MI depending on whether patients (pts) undergo acute 
revascularization. This study examines the utility of providing a wearable cardioverter-defibrillator (WCD, ZOLL) to pts identified by their caregivers to 
be at high risk for SCA during these waiting periods.
Methods: The WCD medical order database was searched for pts who were coded as “recent MI with EF≤35%” or given an ICD9 410.xx diagnostic 
code, then matched to device-recorded data. Patient data was de-identified before analysis.
Results: Between 9/2005 and 7/2011, 9,444 unique pts matched study criteria. The WCD appropriately treated 131. The LVEF was ≤30% in 93, 
30-35% in 16, ≥36% in 4, and not reported in 18 pts. Of the 48% pts not revascularized, 90% had LVEFs ≤30%; of the 52% revascularized pts, 76% 
had LVEFs ≤30%. The median time to WCD therapy was 14 days after start of use for non-revascularized pts, and 8 days for revascularized pts. The 
figure shows the timing of WCD shock events. Survival after the events was 87% in non-revascularized and 93% in revascularized pts.
Conclusions: Although shock rates may overestimate death rates from fatal arrhythmic events, the WCD has the potential for saving 1.3% of pts 
deemed at risk for SCA early after MI despite not being candidates for ICD implantation according to current guideline indications.
